包括 OncoVEX(mGMCSF) 在内的联合免疫治疗在转基因 BRAF 小鼠黑色素瘤中创造了有利的肿瘤免疫微环境

Talimogene Laherparepvec (OncoVEX mGMCSF ), an oncolytic virus, immune checkpoint inhibitor anti-programmed cell death protein 1 (anti-PD1), and BRAF inhibition (BRAFi), are all clinically approved for treatment of melanoma patients and are effective through diverse mechanisms of action. Individually, these therapies also have an effect on the tumor immune microenvironment (TIME).

Evaluating the combination effect of these three therapies on the TIME can help determine when combination therapy is most appropriate for further study. In this study, we use a transgenic murine melanoma model (Tyr::CreER; BRAF CA/+ ; PTEN flox/flox ), to evaluate the TIME in response to combinations of BRAFi, anti-PD1, and OncoVEX mGMCSF .

We find that mice treated with the triple combination BRAFi + anti-PD1 + OncoVEX mGMCSF have decreased tumor growth compared to BRAFi alone and prolonged survival compared to control. Flow cytometry shows an increase in percent CD8 + /CD3 + cytotoxic T Lymphocytes (CTLs) and a decrease in percent FOXP3 + /CD4 + T regulatory cells (Tregs) in tumors treated with OncoVEX mGMCSF compared to mice not treated with OncoVEX mGMCSF .

Immunogenomic analysis at 30d post-treatment shows an increase in Th1 and interferon-related genes in mice receiving OncoVEX mGMCSF + BRAFi. In summary, treatment with combination BRAFi + anti-PD1 + OncoVEX mGMCSF is more effective than any single treatment in controlling tumor growth, and groups receiving OncoVEX mGMCSF had more tumoral infiltration of CTLs and less intratumoral Tregs in the TIME.

This study provides rational basis to combine targeted agents, oncolytic viral therapy, and checkpoint inhibitors in the treatment of melanoma.